News

Teva expects to complete the NDA submission by the end of 2014. CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release (ER) hydrocodone for the management of pain

Myopic CNV (mCNV) develops in about 5%-10% of patients with pathologic myopia, which is a leading cause of blindness and second only to wet age-related macular degeneration (AMD)

Under the deal, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for tafoxiparin in the US, European, CIS and

ABP 501 is being developed by the company as a biosimilar to adalimumab, an anti-TNF-a monoclonal antibody. The trial evaluated the efficacy and safety of ABP 501 compared

The collaboration builds on two independent research programmes at both the ICR and EMD Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.

The trial is being conducted in Germany for a rare form of bile duct cancer for which currently there is no acceptable therapy. About 200 patients will be

In this cohort, three patients were evaluated and they showed that Liposomal Grb-2 is safe and well tolerated with the drug showing signs of anti-leukemia activity. The Phase

NurOwn includes autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors. The company is currently, evaluating NurOwn in a randomized, double-blind, placebo-controlled Phase II clinical

Treatment for glioma, which is the most common form of primary brain cancer, remains a significant unmet medical need. The FDA Orphan Drug Designation provides companies with development